Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares

No definition available.

Name:	trml_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix:	trml_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Acquisition, Maximum Payment

+ References

No definition available.

+ Details

Name:	trml_AssetAcquisitionMaximumPayment
Namespace Prefix:	trml_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Required Royalty Rate Payment, Maximum

+ References

No definition available.

+ Details

Name:	trml_RequiredRoyaltyRatePaymentMaximum
Namespace Prefix:	trml_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Term

+ References

No definition available.

+ Details

Name:	trml_RoyaltyTerm
Namespace Prefix:	trml_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Shares Issued, Interest Percent

+ References

No definition available.

+ Details

Name:	trml_SharesIssuedInterestPercent
Namespace Prefix:	trml_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_AssetAcquisitionAxis=trml_PfizerLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=trml_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=trml_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=trml_SeriesAPreferredUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=trml_PfizerInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Pfizer License Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	May 03, 2022	Mar. 31, 2025	Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense		$ 20,258	$ 11,376
Pfizer License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment	$ 5,000
Royalty rate payment	15.00%
Expected timing satisfaction, period	12 years
Maximum payment on the timing of transaction	$ 20,000
Pfizer License Agreement \| Development and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration, liability	128,000
Pfizer License Agreement \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration, liability	$ 525,000
Series A Preferred Unit \| Pfizer License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued under license agreement (in shares)	7,125,000
Shares issued, price per share (usd per share)	$ 1.00
Equity interest issued and issuable	$ 7,100
Series A Preferred Stock \| Pfizer License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued under license agreement (in shares)	7,125,000
Series A Preferred Stock \| Pfizer Inc. \| Pfizer License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest percent	15.00%